Production process analysis: a review of the device history record confirmed that the device was manufactured and tested according to relevant procedures, and shipped according to manufacturer's specifications.User (surgeon and patient) information analysis: patient (b)(6) index procedure was performed on (b)(6) 2022.Apifix was notified (on 04-oct-2022) that patient (b)(6) was not discharged post operation until (b)(6) 2022 due to a cerebral spinal fluid leak.She had a ct done to confirm this.On (b)(6) 2022 a blood patch procedure was performed, followed by 48 hours of strict flat bed rest, and the patient was discharged on (b)(6) 2022.Risk assessment: the risk of dural leak is a known risk.The event of dural tear/leakage is addressed in the ifu (dms-4472 rev g) as 'potential risks associated with the mid-c system and spine generally'.The current rate of this event is 0.30% and is in line with the rate (0.2%-2.2%) reported in the literature for this type of complication as described in the company's clinical evaluation report ( cer dms-727 rev u ).The risk has been quantified, characterized, and documented as acceptable within a full risk assessment.Most csf leakages occur because of intraoperative dural tears.Although an adverse event has occurred, there does not appear to have been a problem with the device or the way it was used.
|